Map-kinase pathway up or down? Just look at the skin of your patients!

Melanoma Research

Volumn 24, Issue 5, 2014, Pages 421-423

  Robert, Caroline ^a   Thomas, Marina ^a   Mateus, Christina ^a  

^a Universite Paris Sud   (France)

Author keywords

[No Author keywords available]

Indexed keywords

B RAF KINASE INHIBITOR; DABRAFENIB; ERLOTINIB; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; SELUMETINIB; TRAMETINIB; VEMURAFENIB; ANTINEOPLASTIC AGENT; B RAF KINASE; BRAF PROTEIN, HUMAN; IMIDAZOLE DERIVATIVE; INDOLE DERIVATIVE; MITOGEN ACTIVATED PROTEIN KINASE KINASE KINASE; OXIME; PYRIDONE DERIVATIVE; PYRIMIDINONE DERIVATIVE; SULFONAMIDE;

ACNE; CANCER COMBINATION CHEMOTHERAPY; DARIER DISEASE; DRUG HALF LIFE; ENZYME ACTIVATION; ENZYME INHIBITION; HAIR DISEASE; HUMAN; HYPERKERATOSIS; KERATOACANTHOMA; MELANOMA CELL; METASTATIC MELANOMA; MONOTHERAPY; PAPILLOMA; PARONYCHIA; PRIORITY JOURNAL; PUSTULE; RASH; REVIEW; SKIN EXAMINATION; SQUAMOUS CELL CARCINOMA; COMPLICATION; FEMALE; MELANOMA; METABOLISM; SKIN NEOPLASMS;

ACNEIFORM ERUPTIONS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; FEMALE; HUMANS; IMIDAZOLES; INDOLES; MAP KINASE KINASE KINASES; MELANOMA; OXIMES; PROTO-ONCOGENE PROTEINS B-RAF; PYRIDONES; PYRIMIDINONES; SKIN NEOPLASMS; SULFONAMIDES;

EID: 84925944515     PISSN: 09608931     EISSN: 14735636     Source Type: Journal    
DOI: 10.1097/CMR.0000000000000114     Document Type: Review

References (9)

1. Uribe P, Anforth RM, Kefford RF, Fernandez-Peñas P. Acneiform eruption in a patient with metastatic melanoma after ceasing combination dabrafenib/trametinib therapy. Melanoma Res 2014;24:501-503.
2. Peters S, Bouchaab H, Zimmerman S, Bucher M, Gaide O, Letovanec I, et al. Dramatic response of vemurafenib-induced cutaneous lesions upon switch to dual BRAF/MEK inhibition in a metastatic melanoma patient. Melanoma Res 2014;24:496-500.
3. Boussemart L, Routier E, Mateus C, Opletalova K, Sebille G, Kamsu-Kom N, et al. Prospective study of cutaneous side-effects associated with the BRAF inhibitor vemurafenib: a study of 42 patients. Ann Oncol 2013;24:1691-1697.
4. Siegel DH, Mann JA, Krol AL, Rauen KA. Dermatological phenotype in Costello syndrome: consequences of Ras dysregulation in development. Br J Dermatol 2012;166:601-607.
5. Gripp KW, Lin AE. Costello syndrome: a Ras/mitogen activated protein kinase pathway syndrome (rasopathy) resulting from HRAS germline mutations. Genet Med 2012;14:285-292.
6. Su F, Viros A, Milagre C, Trunzer K, Bollag G, Spleiss O, et al. RAS mutations in cutaneous squamous-cell carcinomas in patients treated with BRAF inhibitors. N Engl J Med 2012;366:207-215.
7. Robert C, Arnault J-P, Mateus C. RAF inhibition and induction of cutaneous squamous cell carcinoma. Curr Opin Oncol 2011;23:177-182.
8. Balagula Y, Barth Huston K, Busam KJ, Lacouture ME, Chapman PB, Myskowski PL. Dermatologic side effects associated with the MEK 1/2 inhibitor selumetinib (AZD6244, ARRY-142886). Invest New Drugs 2011;29:1114-1121.
9. Lacouture ME. Mechanisms of cutaneous toxicities to EGFR inhibitors. Nat Rev Cancer 2006;6:803-812.